Navigating the world of weight loss medications can be overwhelming, especially with the recent surge in popularity of drugs like Ozempic, Wegovy, and Mounjaro. If you're feeling confused about these treatments and their differences, you're not alone. Many people struggle to understand the distinctions between these medications, their approved uses, and their effectiveness for weight management. Let's dive into the details to help clarify the landscape of these innovative treatments.
Ozempic
Manufactured by Novo Nordisk
Ozempic, with the active ingredient semaglutide, was initially approved by the Food and Drug Administration (FDA) in December 2017 for the treatment of type 2 diabetes. In the UK, Ozempic is licensed only for treating type 2 diabetes, although it has gained attention online for its weight loss effects. It's important to note that Ozempic is not officially approved for weight loss in the UK.
Wegovy
Manufactured by Novo Nordisk
Wegovy, also containing semaglutide, is specifically approved for weight management in adults with obesity or those who are overweight with weight-related health conditions. The National Institute for Health and Care Excellence (NICE) recommends Wegovy as an option for managing overweight and obesity in adults. To be eligible for a Wegovy prescription in the UK, patients must have:
- A Body Mass Index (BMI) of 30 kg/m² or more (obese), or
- A BMI of 27 kg/m² or more (overweight) with a weight-related medical condition, such as prediabetes or high blood pressure
Mounjaro
Manufactured by Eli Lilly
Mounjaro, with the active ingredient tirzepatide, was initially approved by the FDA in May 2022 for improving blood sugar levels in adults with type 2 diabetes. Recently, it has also been authorized by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for weight loss and management in adults.
Effectiveness for Weight Loss
When comparing the effectiveness of these medications for weight loss, clinical studies have shown promising results:
- Wegovy: Patients can expect an average weight loss of about 15% after one year of treatment.
- Mounjaro: Studies have shown that individuals using Mounjaro can achieve an average weight loss of nearly 22% after one year. In clinical trials, 92% of participants treated with Mounjaro accomplished more than 10% weight loss, with 84% surpassing 15% weight loss.
- Ozempic: While not approved for weight loss, some type 2 diabetics may experience weight loss as a side effect of treatment.
Mechanism of Action
All three medications work by mimicking incretin hormones that regulate appetite and insulin production:
- Ozempic and Wegovy (semaglutide) mimic the action of GLP-1, a hormone that helps regulate appetite.
- Mounjaro (tirzepatide) mimics the action of both GLP-1 and GIP, hormones that help regulate appetite and blood sugar levels.
| Feature | Ozempic | Wegovy | Mounjaro |
| Active Ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Primary UK Approval | Type 2 Diabetes | Weight Loss | Type 2 Diabetes & Weight Loss |
| Mechanism of Action | GLP-1 receptor agonist | GLP-1 receptor agonist | GLP-1 & GIP receptor agonist |
| Average Weight Loss (1 year) | Not approved for weight loss | ~15% | ~22% |
| UK NHS Availability for Weight Loss | No | Yes | Yes |
| Dosing Frequency | Once weekly | Once weekly | Once weekly |
| Administration | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection |
| BMI Requirement for Weight Loss Prescription | N/A | ≥30 kg/m² or ≥27 kg/m² with comorbidities | ≥30 kg/m² or ≥27 kg/m² with comorbidities |
Side Effects and Considerations
All three medications can cause similar side effects, primarily gastrointestinal issues such as nausea, vomiting, and diarrhoea. These side effects often diminish over time as the body adjusts to the medication.
It's crucial to note that these medications are intended for long-term use under medical supervision. They should be used in conjunction with a healthy diet and regular physical activity for optimal results.
Read more: Ozempic vs. Mounjaro: Side Effects, Costs, and Effectiveness
Availability in the UK
Both Wegovy and Mounjaro are available on the NHS and privately in the UK for weight management. Ozempic, while available, is only approved for treating type 2 diabetes.
Curious about Mounjaro, Wegovy, or Ozempic? Our experts are here to help. Whether you're exploring weight loss solutions or have questions about these medications, we're just a click away.
Conclusion
While Ozempic, Wegovy, and Mounjaro all belong to the same class of medications, their approvals and effectiveness for weight loss vary. Wegovy and Mounjaro are both approved for weight management in the UK, with Mounjaro showing slightly higher average weight loss in clinical trials. Ozempic, while not approved for weight loss, may still have some weight loss effects in patients with type 2 diabetes.
As with any medication, it's crucial to consult with a healthcare professional to determine the most appropriate treatment based on individual health needs and circumstances.
